Therapeutic Areas
Explore XBiotech's completed clinical trials, offering a snapshot of key research milestones.
Vilamakitug
Rheumatiod Arthiritis
Vilamakitug
Pancreatic Cancer
Lunlekitug
PK in Healthy Volunteers
Vilamakitug
PK in Healthy Volunteers
Omodenbamab
S. Aureus Bacteremia
Bermekimab
Metastatic Colorectal Cancer
Bermekimab
Symptomatic Colorectal Cancer
Bermekimab
Atopic Dermatitis
Bermekimab
Hidradenitis Supperativa
Bermekimab
Pyoderma Gangrenosum
Bermekimab
Acne Vulgaris
Bermekimab
Restenosis
Bermekimab
Psoriasis
Bermekimab
Type 2 Diabetes
Bermekimab
Leukemia
Bermekimab
Advanced Cancers
Note: Studies are presented in reverse chronological order, with the most recent study listed first. Bermekimab sold to Jenssen in 2019.
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.
